IVUS + NIRS: The PROSPECT II Study

The PROSPECT II study was presented as Late-Breaking Clinical Trials during TCT Connect 2020

Click The PROSPECT II Study for presentation

Latest News:

Supraflex Cruz evidence presented at TCT 2025

In November 2025, EUKON shared an update from Sahajanand Medical…

Read More >

LaaGuarder: first European clinical use announced by EUKON

In January 2026, EUKON announced the first clinical use in…

Read More >

Supraflex Cruz NEVO now available to Italian cath labs

EUKON announced the availability of Supraflex Cruz NEVO to Italian…

Read More >